Table 4.

Clinical trials of anticoagulation for COVID-19.

Trial	Identifier	Sponsor	Patients	Intervention	Comparison	Outcome	Timeframe
COVID-HEP	NCT0445848	University Hospital, Geneva	200 ward or ICU	Therapeutic enoxaparin or UFH	Prophylactic enoxaparin or UFH	Composite ATE, VTE, DIC and all-cause mortality	30 days
X-covid 19	NCT04366960	Niguarda Hospital	2712 ward	Enoxaparin 40 mg QD	Enoxaparin 40 mg BID	DVT by serial ultrasound and PE	30 days
Rapid COVID COAG	NCT04362085	St. Michael's Hospital, Toronto	462 ward with D-dimer >2 time ULN	Therapeutic LMWH or UFH	Prophylactic LMWH, UFH or fondaparinux	Composite ICU admission, non-invasive positive pressure ventilation, mechanical ventilation or all-cause death	28 days
Protect COVID 19	NCT04359277	NYU Langone Health	1000 ward or ICU	Therapeutic LMWH (adjusted for obesity) or UFH	Prophylactic LMWH or UFH (adjusted for obesity)	Composite all = cause mortality, cardiac arrest, VTE, ATE, MI, stroke or shock	30 days
ATTACC	NCT04372589	University of Manitoba	3000 or less (adaptive design) ward and ICU	Therapeutic LMWH or UFH	Usual care	Intubation and mortality	30 days
CORIMMUNO-COAG	NCT04344756	Assistance Pulique - Hopitaux de Paris	808 ward and ICU	Therapeutic tinzaparin or UFH	Prophylactic LMWH or UFH	Survival without ventilation	14 days
COVI-DOSE	NCT04373707	Central Hospital, Nancy, France	602 ward and ICU	Intermediate LMWH	Prophylactic LMWH	VTE and VTE related death	28 days
IMPROVE	NCT04367831	Columbia University	100 ICU	Intermediate LMWH or UFH	Prophylactic LMWH or UFH	VTE and ATE	30 days
HEP-COVID	NCT04401293	Northwell Health	308 ward and ICU	Therapeutic LMWH	Prophylactic or intermediate LMWH or UFH	VTE, ATE and all-cause mortality	30 days

Abbr.: ATE, arterial thromboembolism; BID, twice-daily; COVID-19, coronavirus disease, 2019; DIC, disseminated intravascular coagulation; DVT, deep-vein thrombosis; ICU, intensive care unit; LMWH, low-molecular-weight heparin; QD, once-daily; UFH, unfractionated heparin; VTE, venous thromboembolism.